Janus kinase inhibitors (JAKi) for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee (PRAC) recommended measures.

Z ReguiaiP A BecherelAnne-Claire FougerousseG ChabyJ L PerrotE BegonC Jacobzone-LévêqueC BoulardA BadaouiC PoreauxL DavidN Quiles-TsimaratosD Lons-DanicC FiteA-L LiegeonA PatchinskyJ ParierC GarciaE EstèveR MohtyL Mery-BossardF Maccari

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Keyphrases

risk assessment
atopic dermatitis
electronic health record
heavy metals
emergency department
combination therapy
climate change